Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
enrolment temporariliy stopped for budget considerations
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The ESME Ovarian Cancer database is a multi-center real life database using a retrospective data collection process in 18 French Comprehensive Cancer Center (FCCC) over 20 sites). This database compiles data from existing data available from patient's electronic medical records (EMR).
This database compiles data from existing data available from patient's electronic medical records (EMR) and integrates data from non-structured ans structured sources.
The database includes data related to patient demographics, tumor characteristics (diagnosis, histology, relapses, metastatic disease, etc.), treatments (dates, INN, route of administration, treatment protocols, reason for termination, etc.), and clinical events. Data is collected at each participating site by technicians who are specifically trained for the project using an electronic data collection (eDC) tool.
Data imported into the final database are controlled, recoded, and harmonized before import according to the data management plan. All coding procedures are predefined by the data manager. There is no transmission of individual data; all data are centralized within each center using a shared anonymous format. All data is exclusively obtained retrospectively; no attempts are made to recover non available data from the patient's medical record by contacting healthcare providers or patients.
ESME OC database aims to be a clinical and therapeutic database centralizing existing and available data from different sources used in the participating hospitals. Data do not contain any personal data on patients. In compliance with the authorization delivered by the French Data Protection agency to Unicancer, only aggregated statistical reports and publication are released.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ovarian cancer cohort | Any female treated for ovarian cancer in a French comprehensive cancer centers |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Describe the evolution of therapeutic care in ovarian cancer across the French comprehensive cancer centers | Patient characteristics, tumor characteristics and treatment patterns | baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Describe the impact of therapeutic strategies on survival criteria | Overall survival | From date of diagnosis or first treatment until the date of date of death from any cause. Follow up until 2022. |
| Measure | Description | Time Frame |
|---|---|---|
| Describe the impact of therapeutic strategies on survival criteria | Progression free survival | From date of diagnosis or first treatment until the date of first documented progression or date of death from any cause. Follow up until 2022. |
Inclusion criteria :
Exclusion criteria : None
Not provided
Not provided
Not provided
All consecutive females treated for an ovarian cancer in a French Comprehensive Cancer Center over the selection period.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut de Cancérologie de l'Ouest - Paul Papin | Angers | 49933 | France | |||
| Institut Bergonié |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Result | Romeo, C, P Meeus, M Rodrigues, E Leblanc, A Floquet, P Pautier, F Marchal, et al. " EP967 Natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment ". In ePoster, A513.3-A513. BMJ Publishing Group Ltd, 2019. https://doi.org/10.1136/ijgc-2019-ESGO.1013. | ||
| 34294414 | Result | De Nonneville A, Zemmour C, Frank S, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Sauterey B, Leblanc E, Pomel C, Marchal F, Barranger E, Savoye AM, Guillemet C, Petit T, Pautier P, Rouzier R, Gladieff L, Simon G, Courtinard C, Sabatier R. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. Gynecol Oncol. 2021 Oct;163(1):64-71. doi: 10.1016/j.ygyno.2021.07.019. Epub 2021 Jul 19. | |
| Result | Rodrigues M, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Provensal Gross M, Leblac E, Pomel C, Marchal F, Barranger E, Savoye AM, Guillemet C, Petit T, Pautier P, Rouzier R, Courtinard C, Gladieff L. Real-world clinical outcomes of patients with de novo advanced high-grade epithelial ovarian cancer eligible to niraparib maintenance in France. ESMO Congress, September 16-21, 2021 [ePoster 746P] DOI:https://doi.org/10.1016/j.annonc.2021.08.1188 |
Not provided
Not provided
In accordance with ethical and legal requirements related to the ESME Data Warehouse, individual data from the ESME databases cannot be made available outside Unicancer secured servers.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010051 | Ovarian Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Bordeaux |
| 33076 |
| France |
| Centre François Baclesse | Caen | 14076 | France |
| Centre Jean Perrin | Clermont-Ferrand | 63011 | France |
| Centre Georges-François Leclerc | Dijon | 21079 | France |
| Centre Oscar Lambret | Lille | 59020 | France |
| Centre Léon Bérard | Lyon | 69373 | France |
| Institut Paoli-Calmettes | Marseille | 13273 | France |
| Institut régional du Cancer Montpellier / Val d'Aurelle | Montpellier | 34298 | France |
| Institut de Cancérologie de Lorraine | Nancy | 54511 | France |
| Institut de cancérologie de l'Ouest - René Gauducheau | Nantes | 44805 | France |
| Centre Antoine Lacassagne | Nice | 06189 | France |
| Institut Curie | Paris | 75005 | France |
| Institut Jean Godinot | Reims | 51056 | France |
| Centre Eugène Marquis | Rennes | 35042 | France |
| Centre Henri Becquerel | Rouen | 76038 | France |
| Institut Curie - Hôpital René Huguenin | Saint-Cloud | 92210 | France |
| Centre Paul Strauss | Strasbourg | 67065 | France |
| Institut Claudius Regaud | Toulouse | 31059 | France |
| Institut Gustave Roussy | Villejuif | 94805 | France |
| 35970603 | Result | Thomas QD, Boussere A, Classe JM, Pomel C, Costaz H, Rodrigues M, Ray-Coquard I, Gladieff L, Rouzier R, Rouge TM, Gouy S, Barranger E, Sabatier R, Floquet A, Marchal F, Guillemet C, Polivka V, Martin AL, Colombo PE, Fiteni F. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecol Oncol. 2022 Oct;167(1):11-21. doi: 10.1016/j.ygyno.2022.08.005. Epub 2022 Aug 13. |
| 36011033 | Result | Bini M, Quesada S, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P, Marchal F, Provansal M, Campion L, Causeret S, Gourgou S, Ray-Coquard I, Classe JM, Pomel C, De La Motte Rouge T, Barranger E, Savoye AM, Guillemet C, Gladieff L, Demarchi M, Rouzier R, Courtinard C, Romeo C, Joly F. Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database. Cancers (Basel). 2022 Aug 21;14(16):4040. doi: 10.3390/cancers14164040. |
| 36631150 | Result | Brouillard-Saby F, Saint-Martin C, Ray-Coquard I, Gladieff L, Pomel C, Colombo PE, Classe JM, Chevrier M, Joly F, De la Motte Rouge T, Floquet A, Sabatier R, Barranger E, Costaz H, Leblanc E, Marchal F, Pautier P, Bosquet L, Rodrigues M. Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse. Int J Gynecol Cancer. 2023 Apr 3;33(4):577-584. doi: 10.1136/ijgc-2022-003993. |
| 40349134 | Result | Rippstein N, Zemmour C, Rodrigues M, Ray-Coquard I, Gladieff L, Pautier P, Frenel JS, Costaz H, Lebreton C, Pomel C, Colombo PE, Marchal F, Guillemet C, de la Motte Rouge T, Eberst L, Bosquet L, Deluche E, Sabatier R. PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network. Oncologist. 2025 May 8;30(5):oyaf075. doi: 10.1093/oncolo/oyaf075. |
| 40779880 | Result | Chator C, Chevrier M, Frenel JS, Guyon F, Sabatier R, Pomel C, Rouge TM, Pautier P, Gladieff L, Follana P, Colombo PE, Petit T, Guillemet C, Marchal F, Narducci F, Fumet JD, Rodrigues M, Bosquet L, Rouzier R, Ray-Coquard I. Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database. Gynecol Oncol. 2025 Oct;201:17-25. doi: 10.1016/j.ygyno.2025.08.004. Epub 2025 Aug 7. |
| 41411701 | Result | Papazyan T, Martin E, Pautier P, Guerin-Charbonnel C, Rowinski E, Lecuru F, Joly F, De La Motte Rouge T, Guillemet C, Costaz H, Sabatier R, Barranger E, Colombo PE, Marchal F, Pomel C, Savoye AM, Bosquet L, Ray-Coquard I, Gladieff L, Loaec C, Frenel JS. Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database. Int J Gynecol Cancer. 2026 Feb;36(2):102804. doi: 10.1016/j.ijgc.2025.102804. Epub 2025 Nov 14. |
| Result | Mokarram Dorri N, Foulhioux L, Zemmour C, Thomas QD, Costaz H, Narducci F, Petit T, Loaec C, Laas E, Gyuon F, Cherifi F, Savoye AM, Ferraioli D, Rossi L, De la Motte Rouge T, Marchal F, Gosset M, Pomel C, Martin AL, Lambaudie E. Metastatic sites and surgical management in stage IV ovarian cancer: Is there a place for debulking surgery in FIGO stage IVB patients? A retrospective study from the ESME national cohort. Clin Surg Oncol. 2025; 4(4) |
| 42013623 | Result | Le Bars S, Guerin-Charbonnel C, Martin E, Thomas QD, Costaz H, Pomel C, Marchal F, Narducci F, Gouy S, Laas E, Rossi L, Lambaudie E, Rouzier R, Petit T, Gladieff L, De La Motte Rouge T, Bosquet L, Colombo PE, Classe JM, Loaec C. Advanced high-grade serous ovarian cancer treated with intensive cytoreductive surgery and chemotherapy: prognostic impact of lymph node involvement: analysis of the French national ESME-Unicancer database. Eur J Surg Oncol. 2026 Jun;52(6):111768. doi: 10.1016/j.ejso.2026.111768. Epub 2026 Mar 25. |
| 39481880 | Derived | Becker O, Durand A, Chevrier M, Collet L, Gladieff L, Joly F, Sauterey B, Pomel C, Costaz H, Pautier P, Guillemet C, Rouge TM, Sabatier R, Classe JM, Petit T, Leblanc E, Marchal F, Colombo PE, Barranger E, Savoye AM, Bosquet L, Ray-Coquard I, Carton M, Colomban O, You B, Rodrigues M. Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas. Int J Gynecol Cancer. 2025 May;35(5):101866. doi: 10.1136/ijgc-2024-005815. Epub 2025 Apr 19. |
| D000291 |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |